Tumour-Agnostic Therapies Built on Molecular Insight
Warburg Therapeutics develops therapies that target universal molecular drivers of cancer, regardless of tumour type.
Our Innovative Science
At Warburg Therapeutics, we are building a new foundation for cancer drug discovery—one that goes beyond traditional tumour classifications to unlock therapies with broad clinical reach. Our platform is driven by three core pillars:
Computational Oncology Engine
Our proprietary platform integrates multi-omics data and AI-driven analytics to uncover conserved molecular vulnerabilities across tumour types, enabling the discovery of broadly applicable, high-impact targets.
Precision Target & Biomarker Discovery
We systematically identify and validate novel targets that are essential to cancer cell survival across diverse tumour contexts. Our biomarker-guided strategy ensures therapeutic precision and patient stratification from the outset.
Tumour-Agnostic Therapeutic Development
Warburg is advancing a pipeline of therapies designed to exploit core biological mechanisms common to multiple cancers. This tumour-agnostic approach enables scalable development and addresses significant unmet clinical needs.
Our Therapeutic Pipeline
Warburg Therapeutics is building a differentiated pipeline of tumour-agnostic therapies, guided by our proprietary computational oncology platform and multi-omics discovery engine. Our programs address conserved mechanisms of cancer, independent of tumour type.
WTX-101
Tumour-Agnostic Oncology
A first-in-class antibody-drug conjugate targeting a conserved driver of malignancy. Identified through multi-omics profiling, WTX-101 shows potent, biomarker-defined activity across multiple solid tumours in early clinical studies.
WTX-201
Tumour Microenvironment Modulator
A bispecific antibody designed to activate immune cells and reverse immunosuppression, enhancing anti-cancer responses in multiple solid tumours.
WTX-301
Computationally Guided Oncology
An antibody candidate identified via the Warburg Discovery Platform and advanced through corporate partnership.
Warburg Discovery Platform
Our AI-driven computational oncology platform integrates multi-omics data to identify conserved cancer vulnerabilities. It drives scalable, mechanism-based target and biomarker discovery.
Pipeline Summary
| Program | Modality | Indication(s) | Stage | Highlights |
|---|---|---|---|---|
| WTX-101 | Antibody-Drug Conjugate | Solid Tumours | Discovery | Biomarker-defined, tumour-agnostic ADC |
| WTX-201 | Bispecific Antibody | Solid Tumours | Discovery | Immune modulator, TME targeting |
| WTX-301 | Monoclonal Antibody | To be disclosed | Lead Optimization | Computationally guided, collaborative asset |
| Discovery Platform | Platform Technology | Pan-Oncology | Active | AI-driven multi-omics discovery engine |
The Legacy of Otto Warburg
"Cancer, above all diseases, has countless secondary causes. But, even for cancer, there is only one prime cause..."
Warburg Therapeutics is founded on the enduring insights of Otto Warburg, who was awarded the Nobel Prize in Physiology or Medicine in 1931 for his groundbreaking research on cellular respiration. He discovered that cancer cells preferentially generate energy through glycolysis, even when oxygen is abundant, a phenomenon now known as the Warburg Effect.
This metabolic reprogramming is a fundamental driver of tumorigenesis and sustains multiple cancer hallmarks. It facilitates uncontrolled proliferation, bypass of growth suppressors, evasion of apoptosis, replicative immortality, angiogenesis, invasion and metastasis, deregulated energy metabolism, immune evasion, chronic inflammation, and genomic instability. The Warburg Effect is integrally linked to these processes, reflecting the central role of altered metabolism in supporting the malignant phenotype.
The Warburg Effect also extends beyond the cancer cell itself and plays a crucial role in shaping the tumour microenvironment. By altering nutrient availability and creating metabolic competition, cancer cells change the behavior of immune and stromal cells, weaken immune surveillance, and establish conditions that encourage tumour growth and resistance to therapy.
At Warburg Therapeutics, we focus on targeting these intrinsic metabolic and biological vulnerabilities. By addressing the fundamental differences between cancer and normal tissue, including the complex interactions within the tumour microenvironment, we aim to develop tumour-agnostic therapies with broad clinical relevance and lasting impact.
Let's Connect
We're always open to great ideas, bold collaborations, and talented people. Whether you're a scientist, investor, or innovator — please get in touch, we'd love to hear from you.